Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United States

BACKGROUND: US patients with hemophilia A can receive prophylaxis with extended half-life recombinant factor VIII (rFVIII) products, including efmoroctocog alfa (fragment crystallizable fusion protein) and rurioctocog alfa pegol (antihemophilic factor [recombinant], PEGylated). OBJECTIVE: To evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yanyu, Sun, Shawn X, Fan, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518681/
https://www.ncbi.nlm.nih.gov/pubmed/36188439
http://dx.doi.org/10.2147/JBM.S359510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518681/
https://www.ncbi.nlm.nih.gov/pubmed/36188439
http://dx.doi.org/10.2147/JBM.S359510

Ejemplares similares